Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Express Scripts
Daiichi Sankyo
Healthtrust
UBS
Cerilliant
Medtronic
Chinese Patent Office
Fuji

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CEFEPIME IN PLASTIC CONTAINER

« Back to Dashboard

Clinical Trials for Cefepime In Plastic Container

Trial ID Title Status Sponsor Phase Summary
NCT00020865 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status National Cancer Institute (NCI) Phase 3 RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00020865 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status Jonsson Comprehensive Cancer Center Phase 3 RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of neutropenia in patients who are being treated for cancer. It is not yet known whether levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of neutropenia. PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being treated for cancer.
NCT00044759 Study Comparing the Safety and Efficacy of Piperacillin/Tazobactam to Cefepime in Patients With Hematologic Malignancy or Lymphoma Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 To compare the safety and efficacy of piperacillin/tazobactam (4 g/500 mg) administered intravenously every 6 hours to cefepime (2 g) administered intravenously every 8 hours for the empiric treatment of neutropenic fever in patients with a hematologic malignancy or lymphoma.
NCT00137787 Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases Unknown status Bayer Phase 3 The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
NCT00137787 Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases Unknown status Center for Supporting Hematology-Oncology Trials Phase 3 The aim of this study is to investigate whether intravenous ciprofloxacin is as effective as cefepime for the initial treatment of febrile neutropenia developed in patients with hematologic diseases.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Cefepime In Plastic Container

Condition Name

Condition Name for Cefepime In Plastic Container
Intervention Trials
Febrile Neutropenia 3
Neutropenia 3
Infection 2
Myelodysplastic Syndromes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cefepime In Plastic Container
Intervention Trials
Infection 11
Communicable Diseases 10
Neutropenia 7
Urinary Tract Infections 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cefepime In Plastic Container

Trials by Country

Trials by Country for Cefepime In Plastic Container
Location Trials
United States 52
Spain 6
Brazil 5
Colombia 5
Czech Republic 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cefepime In Plastic Container
Location Trials
Texas 7
New York 5
California 4
Ohio 3
Wisconsin 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cefepime In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Cefepime In Plastic Container
Clinical Trial Phase Trials
Phase 4 6
Phase 3 12
Phase 2 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cefepime In Plastic Container
Clinical Trial Phase Trials
Completed 16
Recruiting 8
Terminated 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cefepime In Plastic Container

Sponsor Name

Sponsor Name for Cefepime In Plastic Container
Sponsor Trials
Wockhardt 5
M.D. Anderson Cancer Center 4
Quintiles, Inc. 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cefepime In Plastic Container
Sponsor Trials
Other 42
Industry 21
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Queensland Health
Argus Health
Fish and Richardson
Colorcon
Medtronic
US Army
Julphar
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.